1. Tosetti, C, Nanni, I. Use of proton pump inhibitors in general practice. World J Gastrointest Pharmacol Therapeut. 2017;8(3):180-185. doi:10.4292/wjgpt.v8.i3.180.
Google Scholar | Crossref | Medline2. Millar, TP, Wong, S, Odierna, DH, Bero, LA. Applying the essential medicines concept to US preferred drug lists. Am J Publ Health. 2011;101(8):1444-1448. doi:10.2105/AJPH.2010.3000054.
Google Scholar | Crossref | Medline3. Peura, DA, Berardi, RR, Gonzalez, J, Brunetti, L. The value of branded proton pump inhibitors: formulary considerations. P T : A Peer-Reviewed Journal for Formulary Management. 2011;36(7):434-445.
Google Scholar | Medline4. Martin, RM, Dunn, NR, Freemantle, S, Shakir, S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol. 2000;50(4):366-372. doi:10.1046/j.1365-2125.2000.00262.x.
Google Scholar | Crossref | Medline5. Schoenfeld, AJ, Grady, D. Adverse Effects Associated with Proton Pump Inhibitors. JAMA Internal Medicine. 2016;176(2):172-174.
Google Scholar | Crossref | Medline | ISI6. Hennekens, CH, DeMets, D. Statistical Association and Causation. J Am Med Assoc. 2011;305(11):1134.
Google Scholar | Crossref | Medline | ISI7. Hennekens, CH, DeMets. The Need for Large-Scale Randomized Evidence Without Undue Emphasis on Small Trials, Meta-analyses, or Subgroup Analyses. J Am Med Assoc. 2009;302(21):2361-2362.
Google Scholar | Crossref | Medline | ISI8. Hennekens, C, Buring, J. Epidemiology in Medicine. Boston, Massachusetts: Little, Brown and Company; 1987.
Google Scholar9. Risk Reduction of Cognitive Decline and Dementia: WHO Guidelines. Geneva: World Health Organization; 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542796/
Google Scholar10. Badiola, N, Alcalde, V, Pujol, A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One. 2013;8(3):e58837. doi:10.1371/journal.pone.0058837.
Google Scholar | Crossref | Medline11. Gomm, W, von Holt, K, Thomé, F, et al. Association of proton pump inhibitors with risk of dementia. JAMA Neurology. 2016;73(4):410-416.
Google Scholar | Crossref | Medline12. Gray, SL, Walker, RL, Dublin, S, et al. Proton Pump Inhibitor Use and Dementia Risk: Prospective Population-Based Study. J Am Geriatr Soc. 2018;66:247-253.
Google Scholar | Crossref | Medline13. Haenisch, B, von Holt, K, Wiese, B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatr Clin Neurosci. 2015;265:419-428.
Google Scholar | Crossref | Medline | ISI14. Lochhead, P, Hagan, K, Joshi, AD, et al. Association between proton pump inhibitor use and cognitive function in women. Gastroenterology. 2017;153(3):971-e4.
Google Scholar | Crossref | Medline15. Goldstein, FC, Steenland, K, Zhao, L, Wharton, W, Levey, AI, Hajjar, I. Proton pump inhibitors and risk of mild cognitive impairment and dementia. J Am Geriatr Soc. 2017;65:1969-1974.
Google Scholar | Crossref | Medline16. Khan, MA, Yuan, Y, Iqbal, U, et al. No association linking short-term proton pump inhibitor use to dementia: systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2020;115(5):671-678.
Google Scholar | Crossref | Medline17. Liao, K-F, Chuang, H-Y, Lai, S-W. Association between proton pump inhibitor use and Alzheimer's disease in older adults. J Am Geriatr Soc. 2018;66:1848-1850.
Google Scholar | Crossref | Medline18. Moayyedi, P, Eikelboom, JW, Bosch, J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157:682-691.
Google Scholar | Crossref | Medline